+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Influenza A Virus, H5N1 Subtype Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 104 Pages
  • May 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5602728
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest disease pipeline guide Influenza A Virus, H5N1 Subtype Infections - Drugs In Development, 2022, provides an overview of the Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline landscape.

H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. Symptoms include fever and cough, acute respiratory distress, shortness of breath/difficulty breathing, abdominal pain and diarrhea. Predisposing factors include work with poultry, touch an infected bird and eating raw or undercooked poultry meat. Treatment includes antiviral medications.

Report Highlights


The publisher's latest pipeline guide Influenza A Virus, H5N1 Subtype Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 4, 1, 19, 6 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 2, 5 and 1 molecules, respectively.

Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of TablesList of FiguresIntroduction
Report Coverage
Influenza A Virus, H5N1 Subtype Infections - Overview
Influenza A Virus, H5N1 Subtype Infections - Therapeutics Development
Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Influenza A Virus, H5N1 Subtype Infections - Therapeutics Assessment
Assesement by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Influenza A Virus, H5N1 Subtype Infections - Companies Involved in Therapeutics Development
Influenza A Virus, H5N1 Subtype Infections - Drug Profiles
Influenza A Virus, H5N1 Subtype Infections - Dormant Projects
Influenza A Virus, H5N1 Subtype Infections - Discontinued Products
Influenza A Virus, H5N1 Subtype Infections - Product Development Milestones
Featured NewsAppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact UsDisclaimer
List of Tables
  • Number of - Products under Development for Influenza A Virus, H5N1 Subtype Infections, 2022
  • Number of - Products under Development by Companies, 2022
  • Number of - Products under Development by Companies, 2022 (Contd..1)
  • Number of - Products under Development by Universities/Institutes, 2022
  • Products under Development by Companies, 2022
  • Products under Development by Companies, 2022 (Contd..1)
  • Products under Development by Universities/Institutes, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, 2022
Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, 2022 (Contd..1)
Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, 2022 (Contd..2)
Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, 2022 (Contd..3)
Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, 2022 (Contd..4)
Influenza A Virus, H5N1 Subtype Infections - Discontinued Products, 2022
List of Figures
  • Number of - Products under Development for Influenza A Virus, H5N1 Subtype Infections, 2022
  • Number of - Products under Development by Companies, 2022
  • Number of - Products under Development by Universities/Institutes, 2022
  • Number of Products by Targets, 2022
  • Number of Products by Stage and Targets, 2022
  • Number of Products by Mechanism of Actions, 2022
  • Number of Products by Stage and Mechanism of Actions, 2022
  • Number of Products by Routes of Administration, 2022
  • Number of Products by Stage and Routes of Administration, 2022
  • Number of Products by Top 10 Molecule Types, 2022
  • Number of Products by Stage and Top 10 Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abzyme Therapeutics LLC
  • AlphaVax Inc
  • Aphios Corp
  • AusBio Ltd
  • BiondVax Pharmaceuticals Ltd
  • Celdara Medical LLC
  • Chicago Biosolutions Inc
  • CHO Pharma Inc
  • Cocrystal Pharma Inc
  • Curevac NV
  • CytoAgents Inc
  • Declion Pharmaceuticals